Eli Lilly Just Scored a European Weight Loss Pill Approval -- and the Growth Story Keeps Getting BiggerThe Motley Fool • 08/14/26
Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting BiggerThe Motley Fool • 08/14/26
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?Zacks Investment Research • 08/13/26
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)Seeking Alpha • 08/12/26
Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutideMarket Watch • 08/12/26
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutideReuters • 08/12/26
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black marketPRNewsWire • 08/12/26
Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.CNBC • 08/11/26
17 S&P 500 companies with growing revenue and profit margins — and some of their stocks are cheapMarket Watch • 08/10/26